You searched for "community"

1363 results found

ENT UK Head & Neck Meeting

The ENT UK Head and Neck Evidence-Based Management Meeting focusing on malignancy of the nose and paranasal sinuses was held in the historic market town of York. The multidisciplinary approach required to manage this complex disease was reflected in the speaker lineup, with national representation from ENT, maxillofacial and plastic surgery, oncology, palliative medicine, histopathology and radiology.

Paroxysmal downbeating nystagmus and proton pump inhibitors

This case report highlights the effect of long-term use of proton pump inhibitors on the vestibular system. The authors reported a case of a 70-year-old woman who was admitted with delirium, ataxia, slurred speech and slowness of thought. She had...

History of Hearing Device

Alex Griffiths-Brown, BSc(Hons), MRes, Senior Audiologist, The Shrewsbury and Telford Hospitals NHS Trust, Shrewsbury, UK. E: alex.griffiths-brown@nhs.netTwitter: @griffithsbrown1 When I was asked to edit ENT&A Nov/Dec 2023 on the history of hearing devices, I knew it was going to be...

Is there increased cardiovascular risk with macrolide antibiotics?

This month’s Ed’s Choice delightfully reviews the potential cardiovascular consequences of long-term macrolide use in the treatment of chronic rhinosinusitis. This used to be one of my ‘go-to’ topics of conversation at home after a bad day at work, although...

Identifying congenital CMV: the screening debate

Congenital cytomegalovirus (cCMV) is a significant global public health burden and is the biggest non-genetic cause of childhood hearing loss, as well as being an important cause of neurodevelopmental delay. Despite a study concluding that there was not enough evidence...

Congratulations to the 2023 OSSEO Student Investigator Scholarship Winners

Oticon Medical is delighted to announce that three of their investigator-initiated research collaborators have been awarded the prestigious Student Investigator and Early Career Scholarships sponsored by the University of Colorado School of Medicine.

UK clinics providing Lenire tinnitus treatment device double in latest expansion

Neuromod Devices, the medical device company that specialises in tinnitus treatment, has announced they are partnering with four UK clinics to expand the availability of Lenire®, the clinically proven tinnitus treatment device. Tinnitus, which is commonly known as “ringing in...

Neuromod expands availability of Lenire tinnitus treatment device in Europe with 19 new clinical partnerships

Neuromod Devices, the technology company that specialises in medical devices for tinnitus treatment, has announced 19 new clinical partnerships to expand the availability of the Lenire tinnitus treatment device in Europe. This latest expansion will significantly increase the number of...

Temporal bone trauma

Introduction Temporal bone injuries represent one of the more complex management problems presenting to the otolaryngologist. This is largely due to difficulties in assessment and the frequent delays in referral, often as a result of other injuries demanding more immediate...

Foundations of Aural Rehabilitation: Children, Adults and Their Family Members – Sixth Edition

This book provides a plethora of information relating to aural rehabilitation. The author has taken a multi-faceted approach, combining firm evidence-based perspectives with an evaluation of the scientific foundations of current clinical practises. This book is mainly aimed at those...

Auditory deprivation and single-sided deafness

In cases of bilateral auditory deprivation, there is clear evidence of an inverse relationship between performance after cochlear implantation and the length of severe to profound deafness prior to implantation (i.e. the longer the deprivation the poorer the outcome on...

Management of patulous eustachian tube dysfunction

Idiopathic sudden sensorineural hearing loss (iSSNHL) is defined as a hearing loss of 30 dB or more at three contiguous frequencies within 72 hours, with acute low-tone hearing loss (ALHL) excluded from this category. Despite standard treatment, outcomes vary: one-third...